India's Jubilant signs licensing deal for Gilead's potential COVID-19 drug | ||
Tuesday, 12 May 2020 ()
India's Jubilant Life Sciences Ltd said on Tuesday it had signed a non-exclusive licensing agreement for selling Gilead Sciences Inc's experimental COVID-19 treatment remdesivir in 127 countries, including India. |